TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
Phase II, open label study in which patients with metastatic melanoma (stage III or IV) who have cancer which is not considered curable by surgery will receive intratumoral injections of TNFerade™ plus radiation as a 4-week treatment, followed by a 3 year follow-up period.
|Official Title:||A Phase II, Open Label, Single Arm, "Proof of Concept" Study of TNFerade™ Plus Radiation in Patients With Metastatic Melanoma|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00261404
|United States, Texas|
|Mary Crowley Medical Research Center|
|Dallas, Texas, United States, 75201|